Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q3 2017 · 10-Q
Revenue$123.33K$123.33K+38.6% vs Q3 2016 Net Income-$4.29M-$4.29MN/M vs Q3 2016 EPS Diluted-$1.41-$1.41N/M vs Q3 2016 Operating Income-$5,797,621N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$6,709,831N/M Margins · derivedOperating margin-4700.9%+6450.2 pt vs Q3 2016
Net margin-3480.1%+7970.8 pt vs Q3 2016
ended Sep 30, 2017 · filed Nov 9, 2017 · 40 d after period end